# Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

> **NCT05522192** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hui Zeng** · enrollment: 70 (estimated)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Mitoxantrone liposome
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05522192
- **Lead sponsor:** Hui Zeng
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-21
- **Primary completion:** 2025-11
- **Final completion:** 2026-05
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522192, "Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05522192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*